Cytokinetics, Inc.

( )
CYTK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -0.01%170.190.7%$968.89m
PFEPfizer Inc. 0.42%49.780.9%$831.56m
ABBVAbbVie, Inc. -0.06%140.261.9%$828.10m
MRKMerck & Co., Inc. 1.18%89.530.7%$782.75m
LLYEli Lilly & Co. 0.15%302.941.1%$765.74m
BMYBristol-Myers Squibb Co. 1.59%74.971.0%$667.48m
SIGASIGA Technologies, Inc. 2.70%22.790.0%$421.60m
AZNAstraZeneca Plc 1.18%65.891.0%$366.83m
ALNYAlnylam Pharmaceuticals, Inc. -3.19%223.378.1%$270.23m
GBTGlobal Blood Therapeutics, Inc. -0.02%66.595.6%$260.89m
GSKGSK Plc -0.79%39.990.3%$212.92m
HZNPHorizon Therapeutics Plc -3.63%67.125.4%$204.87m
NVSNovartis AG 1.39%87.130.2%$176.66m
CCXIChemoCentryx, Inc. -0.20%50.792.9%$168.36m
SGENSeagen Inc. -1.53%175.605.7%$163.66m

Company Profile

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.